Report Overview
Report Overview
Peripheral artery disease (PAD) is a narrowing of the arteries other than those that supply the heart or the brain. When narrowing occurs in the heart, it is called coronary artery disease, while, in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication. Other symptoms including skin ulcers, bluish skin, cold skin, or poor nail and hair growth may occur in the affected leg. Complications may include an infection or tissue death which may require amputation; coronary artery disease, or stroke.[3] Up to 50% of cases of PAD are without symptoms.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The global Peripheral Arterial Disease (PAD) Therapeutics market size was estimated at USD 3259.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 5.30% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Peripheral Arterial Disease (PAD) Therapeutics market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Peripheral Arterial Disease (PAD) Therapeutics market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Peripheral Arterial Disease (PAD) Therapeutics market.
Global Peripheral Arterial Disease (PAD) Therapeutics Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)
Market Segmentation (by Type)
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others
Market Segmentation (by Application)
Hospitals
Clinics
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Peripheral Arterial Disease (PAD) Therapeutics Market
Overview of the regional outlook of the Peripheral Arterial Disease (PAD) Therapeutics Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Peripheral Arterial Disease (PAD) Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the markets competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porters five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Peripheral Arterial Disease (PAD) Therapeutics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Table of Contents
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Peripheral Arterial Disease (PAD) Therapeutics
- 1.2 Key Market Segments
- 1.2.1 Peripheral Arterial Disease (PAD) Therapeutics Segment by Type
- 1.2.2 Peripheral Arterial Disease (PAD) Therapeutics Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Peripheral Arterial Disease (PAD) Therapeutics Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size (M USD) Estimates and Forecasts (2020-2035)
- 2.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Sales Estimates and Forecasts (2020-2035)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 2.1 Global Market Overview
- 3 Peripheral Arterial Disease (PAD) Therapeutics Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global Peripheral Arterial Disease (PAD) Therapeutics Product Life Cycle
- 3.3 Global Peripheral Arterial Disease (PAD) Therapeutics Sales by Manufacturers (2020-2025)
- 3.4 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Peripheral Arterial Disease (PAD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Peripheral Arterial Disease (PAD) Therapeutics Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 Peripheral Arterial Disease (PAD) Therapeutics Market Competitive Situation and Trends
- 3.8.1 Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Peripheral Arterial Disease (PAD) Therapeutics Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 Peripheral Arterial Disease (PAD) Therapeutics Industry Chain Analysis
- 4.1 Peripheral Arterial Disease (PAD) Therapeutics Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Peripheral Arterial Disease (PAD) Therapeutics Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global Peripheral Arterial Disease (PAD) Therapeutics Market Porters Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to Peripheral Arterial Disease (PAD) Therapeutics Market
- 5.7 ESG Ratings of Leading Companies
- 6 Peripheral Arterial Disease (PAD) Therapeutics Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Type (2020-2025)
- 6.3 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2020-2025)
- 6.4 Global Peripheral Arterial Disease (PAD) Therapeutics Price by Type (2020-2025)
- 7 Peripheral Arterial Disease (PAD) Therapeutics Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Sales by Application (2020-2025)
- 7.3 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size (M USD) by Application (2020-2025)
- 7.4 Global Peripheral Arterial Disease (PAD) Therapeutics Sales Growth Rate by Application (2020-2025)
- 8 Peripheral Arterial Disease (PAD) Therapeutics Market Sales by Region
- 8.1 Global Peripheral Arterial Disease (PAD) Therapeutics Sales by Region
- 8.1.1 Global Peripheral Arterial Disease (PAD) Therapeutics Sales by Region
- 8.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Region
- 8.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region
- 8.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region
- 8.2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region
- 8.3 North America
- 8.3.1 North America Peripheral Arterial Disease (PAD) Therapeutics Sales by Country
- 8.3.2 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Sales by Country
- 8.4.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Peripheral Arterial Disease (PAD) Therapeutics Sales by Region
- 8.5.2 Asia Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America Peripheral Arterial Disease (PAD) Therapeutics Sales by Country
- 8.6.2 South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Sales by Region
- 8.7.2 Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 8.1 Global Peripheral Arterial Disease (PAD) Therapeutics Sales by Region
- 9 Peripheral Arterial Disease (PAD) Therapeutics Market Production by Region
- 9.1 Global Production of Peripheral Arterial Disease (PAD) Therapeutics by Region(2020-2025)
- 9.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Region (2020-2025)
- 9.3 Global Peripheral Arterial Disease (PAD) Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Peripheral Arterial Disease (PAD) Therapeutics Production
- 9.4.1 North America Peripheral Arterial Disease (PAD) Therapeutics Production Growth Rate (2020-2025)
- 9.4.2 North America Peripheral Arterial Disease (PAD) Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Peripheral Arterial Disease (PAD) Therapeutics Production
- 9.5.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Production Growth Rate (2020-2025)
- 9.5.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Peripheral Arterial Disease (PAD) Therapeutics Production (2020-2025)
- 9.6.1 Japan Peripheral Arterial Disease (PAD) Therapeutics Production Growth Rate (2020-2025)
- 9.6.2 Japan Peripheral Arterial Disease (PAD) Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Peripheral Arterial Disease (PAD) Therapeutics Production (2020-2025)
- 9.7.1 China Peripheral Arterial Disease (PAD) Therapeutics Production Growth Rate (2020-2025)
- 9.7.2 China Peripheral Arterial Disease (PAD) Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 AstraZeneca Plc. (UK)
- 10.1.1 AstraZeneca Plc. (UK) Basic Information
- 10.1.2 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.1.4 AstraZeneca Plc. (UK) Business Overview
- 10.1.5 AstraZeneca Plc. (UK) SWOT Analysis
- 10.1.6 AstraZeneca Plc. (UK) Recent Developments
- 10.2 Bayer HealthCare Pharmaceuticals (Germany)
- 10.2.1 Bayer HealthCare Pharmaceuticals (Germany) Basic Information
- 10.2.2 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.2.4 Bayer HealthCare Pharmaceuticals (Germany) Business Overview
- 10.2.5 Bayer HealthCare Pharmaceuticals (Germany) SWOT Analysis
- 10.2.6 Bayer HealthCare Pharmaceuticals (Germany) Recent Developments
- 10.3 Bristol-Myers Squibb Company (US)
- 10.3.1 Bristol-Myers Squibb Company (US) Basic Information
- 10.3.2 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.3.4 Bristol-Myers Squibb Company (US) Business Overview
- 10.3.5 Bristol-Myers Squibb Company (US) SWOT Analysis
- 10.3.6 Bristol-Myers Squibb Company (US) Recent Developments
- 10.4 Merck and Co., Inc. (US)
- 10.4.1 Merck and Co., Inc. (US) Basic Information
- 10.4.2 Merck and Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.4.3 Merck and Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.4.4 Merck and Co., Inc. (US) Business Overview
- 10.4.5 Merck and Co., Inc. (US) Recent Developments
- 10.5 Proteon Therapeutics, Inc. (US)
- 10.5.1 Proteon Therapeutics, Inc. (US) Basic Information
- 10.5.2 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.5.4 Proteon Therapeutics, Inc. (US) Business Overview
- 10.5.5 Proteon Therapeutics, Inc. (US) Recent Developments
- 10.6 Sanofi S.A. (France)
- 10.6.1 Sanofi S.A. (France) Basic Information
- 10.6.2 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.6.4 Sanofi S.A. (France) Business Overview
- 10.6.5 Sanofi S.A. (France) Recent Developments
- 10.7 Symic Bio, Inc. (US)
- 10.7.1 Symic Bio, Inc. (US) Basic Information
- 10.7.2 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.7.4 Symic Bio, Inc. (US) Business Overview
- 10.7.5 Symic Bio, Inc. (US) Recent Developments
- 10.8 TheraVasc Inc. (US)
- 10.8.1 TheraVasc Inc. (US) Basic Information
- 10.8.2 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.8.4 TheraVasc Inc. (US) Business Overview
- 10.8.5 TheraVasc Inc. (US) Recent Developments
- 10.9 AnGes MG, Inc. (Japan)
- 10.9.1 AnGes MG, Inc. (Japan) Basic Information
- 10.9.2 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.9.4 AnGes MG, Inc. (Japan) Business Overview
- 10.9.5 AnGes MG, Inc. (Japan) Recent Developments
- 10.10 Athersys, Inc. (US)
- 10.10.1 Athersys, Inc. (US) Basic Information
- 10.10.2 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.10.4 Athersys, Inc. (US) Business Overview
- 10.10.5 Athersys, Inc. (US) Recent Developments
- 10.11 Betagenon AB (Sweden)
- 10.11.1 Betagenon AB (Sweden) Basic Information
- 10.11.2 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.11.4 Betagenon AB (Sweden) Business Overview
- 10.11.5 Betagenon AB (Sweden) Recent Developments
- 10.12 miRagen Therapeutics, Inc. (US)
- 10.12.1 miRagen Therapeutics, Inc. (US) Basic Information
- 10.12.2 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.12.4 miRagen Therapeutics, Inc. (US) Business Overview
- 10.12.5 miRagen Therapeutics, Inc. (US) Recent Developments
- 10.13 Multi Gene Vascular Systems Ltd (Israel)
- 10.13.1 Multi Gene Vascular Systems Ltd (Israel) Basic Information
- 10.13.2 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.13.4 Multi Gene Vascular Systems Ltd (Israel) Business Overview
- 10.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Developments
- 10.14 ViroMed Co. Ltd. (Korea)
- 10.14.1 ViroMed Co. Ltd. (Korea) Basic Information
- 10.14.2 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Product Overview
- 10.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Product Market Performance
- 10.14.4 ViroMed Co. Ltd. (Korea) Business Overview
- 10.14.5 ViroMed Co. Ltd. (Korea) Recent Developments
- 10.1 AstraZeneca Plc. (UK)
- 11 Peripheral Arterial Disease (PAD) Therapeutics Market Forecast by Region
- 11.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Forecast
- 11.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size Forecast by Country
- 11.2.3 Asia Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size Forecast by Region
- 11.2.4 South America Peripheral Arterial Disease (PAD) Therapeutics Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of Peripheral Arterial Disease (PAD) Therapeutics by Country
- 12 Forecast Market by Type and by Application (2026-2035)
- 12.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Forecast by Type (2026-2035)
- 12.1.1 Global Forecasted Sales of Peripheral Arterial Disease (PAD) Therapeutics by Type (2026-2035)
- 12.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Forecast by Type (2026-2035)
- 12.1.3 Global Forecasted Price of Peripheral Arterial Disease (PAD) Therapeutics by Type (2026-2035)
- 12.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Forecast by Application (2026-2035)
- 12.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Sales (K Units) Forecast by Application
- 12.2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size (M USD) Forecast by Application (2026-2035)
- 12.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Forecast by Type (2026-2035)
- 13 Conclusion and Key Findings